Expanding the clinical phenotype of SNCA duplication carriers-Reference-Cited by-同舟云学术

Expanding the clinical phenotype of SNCA duplication carriers

Published:2009-06-26 Issue:12 Volume:24 Page:1811-1819
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov. Disord.

Author:

Nishioka Kenya,Ross Owen A.,Ishii Kenji,Kachergus Jennifer M.,Ishiwata Kiichi,Kitagawa Mayumi,Kono Satoshi,Obi Tomokazu,Mizoguchi Koichi,Inoue Yuichi,Imai Hisamasa,Takanashi Masashi,Mizuno Yoshikuni,Farrer Matthew J.,Hattori Nobutaka

Funder

MEXT of Japan

Eli-Lilly scholarship

Juntendo University

Tokyo Medical University

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.22682/fullpdf

Reference34 articles.

1. Alpha-synuclein in Lewy bodies;Spillantini;Nature,1997

2. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease;Polymeropoulos;Science,1997

3. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease;Kruger;Nat Genet,1998

4. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia;Zarranz;Ann Neurol,2004

5. Alpha-synuclein locus triplication causes Parkinson's disease;Singleton;Science,2003

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs;Science Advances;2024-09-13

2. The diversity ofSNCAtranscripts in neurons, and its impact on antisense oligonucleotide therapeutics;2024-05-31

3. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson’s disease patient with SNCA duplication;Stem Cell Research;2024-02

4. The Landscape of Monogenic Parkinson’s Disease in Populations of Non-European Ancestry: A Narrative Review;Genes;2023-11-17

5. Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease;Pharmacology & Therapeutics;2023-09